Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Ellipta“
Suchtreffer
Begriffe & Kennungen
Elebrato Ellipta · 4.5 · Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicist
Eintrag öffnenElebrato Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/umeclidinium/vilanterol at clinical d
Eintrag öffnenElebrato Ellipta · 4.5 · Co-administration of Elebrato Ellipta with other long-acting muscarinic antagonists or long-acting beta2- adre
Eintrag öffnenElebrato Ellipta · 4.5 · Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diureti
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate and vilanterol are rapidly cleared by extensive first pass metabolism mediated by enzyme C
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The
Eintrag öffnenElebrato Ellipta · 4.5 · Interaction with CYP2D6 inhibitors/CYP2D6 polymorphism
Eintrag öffnenElebrato Ellipta · 4.5 · Interaction with CYP3A4 inhibitor
Eintrag öffnenElebrato Ellipta · 4.5 · Interaction with P-glycoprotein inhibitors
Eintrag öffnenElebrato Ellipta · 4.5 · Interaction with beta-blockers
Eintrag öffnenElebrato Ellipta · 4.5 · Other long acting antimuscarinics and long acting beta2- adrenergic agonists
Eintrag öffnenElebrato Ellipta · 4.5 · Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium
Eintrag öffnenElebrato Ellipta · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenElebrato Ellipta · 4.8 Undesirable effects · 1
Eintrag öffnenElebrato Ellipta · 4.8 · 7 System Organ Class Adverse reactions Frequency
Eintrag öffnenElebrato Ellipta · 4.8 · 8 comparable with that observed in the fluticasone furoate/vilanterol (FF/VI) 100/25 arm of FF/VI clinical stu
Eintrag öffnenElebrato Ellipta · 4.8 · Adverse reactions are listed by MedDRA system organ class.
Eintrag öffnenElebrato Ellipta · 4.8 · Description of selected adverse reactions
Eintrag öffnenElebrato Ellipta · 4.8 · In a 52-week study, with a total of 10 355 patients with COPD and a history of moderate or severe exacerbation
Eintrag öffnenElebrato Ellipta · 4.8 · Infections and infestations Pneumonia Common Upper respiratory tract infection Bronchitis Pharyngitis Rhinitis
Eintrag öffnen